Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

154 7 Immunosuppresive Factors in Cancer
307 Ho, S. B. and Y. S. Kim. 1991. Carbohydrate
antigens on cancer-associated mucin-like
molecules. Semin. Cancer Biol.
2: 389.
308 Ho, J. J. 2000. Mucins in the diagnosis
and therapy of pancreatic cancer. Curr.
Pharm. Des. 6: 1881.
309 Agrawal, B., S. J. Gendler and B. M.
Longenecker. 1998. The biological role
of mucins in cellular interactions and
immune regulation: prospects for cancer
immunotherapy. Mol. Med. Today 4:
397.
310 Miles, D. W. and J. Taylor-Papadimitriou.
1999. Therapeutic aspects of
polymorphic epithelial mucin in adenocarcinoma.
Pharmacol. Ther. 82: 97.
311 Reddish, M. A., G. D. MacLean,
S. Poppema, A. Berg and B. M. Longenecker.
1996. Pre-immunotherapy
serum CA27. 29 (MUC-1) mucin level
and CD69 + lymphocytes correlate with
effects of Theratope sialyl-Tn-KLH cancer
vaccine in active specific immunotherapy.
Cancer Immunol. Immunother.
42: 303.
312 MacLean, G. D., M. A. Reddish and
B. M. Longenecker. 1997. Prognostic
significance of preimmunotherapy
serum CA27. 29 (MUC-1) mucin level
after active specific immunotherapy of
metastatic adenocarcinoma patients.
J. Immunother. 20: 70.
313 Agrawal, B., M. J. Krantz, M. A. Reddish
and B. M. Longenecker. 1998.
Cancer-associated MUC1 mucin inhibits
human T-cell proliferation, which is
reversible by IL-2. Nat. Med. 4: 43.
314 Kim, J. A., M. A. Dayton,W. Aldrich
and P. L. Triozzi. 1999. Modulation of
CD4 cell cytokine production by colon
cancer-associated mucin. Cancer Immunol.
Immunother. 48: 525.
315 Chang, J. F., H. L. Zhao, J. Phillips
and G. Greenburg. 2000. The epithelial
mucin, MUC1, is expressed on resting
T lymphocytes and can function as
a negative regulator of T cell activation.
Cell Immunol. 201: 83.
316 Vishwanatha, J. K.,Y. Chiang,
K. D. Kumble, M. A. Hollingsworth
and P. M. Pour. 1993. Enhanced expression
of annexin II in human pancreatic
carcinoma cells and primary
pancreatic cancers. Carcinogenesis 14:
2575.
317 Schwartz-Albiez, R., K. Koretz,
P. Moller and G. Wirl. 1993. Differential
expression of annexins I and II in normal
and malignant human mammary
epithelial cells. Differentiation 52: 229.
318 Reeves, S. A., C. Chavez-Kappel,
R. Davis, M. Rosenblum and M. A. Israel.
1992. Developmental regulation
of annexin II (Lipocortin 2) in human
brain and expression in high grade
glioma. Cancer Res. 52: 6871.
319 Roseman, B. J., A. Bollen, J. Hsu,
K. Lamborn and M. A. Israel. 1994.
Annexin II marks astrocytic brain tumors
of high histologic grade. Oncol.
Res. 6: 561.
320 Emoto, K., H. Sawada,Y. Yamada,
H. Fujimoto,Y. Takahama, M. Ueno,
T. Takayama, H. Uchida, K. Kamada, A.
Naito, S. Hirao and Y. Nakajima. 2001.
Annexin II overexpression is correlated
with poor prognosis in human gastric
carcinoma. Anticancer Res. 21: 1339.
321 Aarli, A., J. T. Skeie, E. K. Kristoffersen,
A. Bakke and E. Ulvestad. 1997.
Inhibition of phytohaemagglutinin-induced
lymphoproliferation by soluble
annexin II in sera from patients with
renal cell carcinoma. APMIS 105: 699.
322 Aarli, A. and R. Matre. 1998. Suppression
of immunoglobulin secretion by
soluble annexin II. Scand. J. Immunol.
48: 522.
323 Reiter,W., P. Stieber, C. Reuter, D.
Nagel, U. Lau-Werner and R. Lamerz.
2000. Multivariate analysis of the prognostic
value of CEA and CA 19±9
serum levels in colorectal cancer. Anticancer
Res. 20: 5195.
324 Rivoltini, L., G. Cattoretti, F. Arienti,
A. Mastroianni and G. Parmiani.
1992. CEA and NCA expressed
by colon carcinoma cells affect their interaction
with and lysability by activated
lymphocytes. Int. J. Biol. Markers 7: 143.
325 Pellegrini, P., A. M. Berghella,
T. Del Beato, D. Maccarone, S. Cencioni,
D. Adorno and C. U. Casciani.
1997. The sCEA molecule suppressive
role in NK and T H1 cell functions in
colorectal cancer. Cancer Biother. Radiopharm.
12: 257.